Invicta Diagnostic (NSE:INVICTA) EBIT: ₹72.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:INVICTA Invicta Diagnostic Ltd NSE:INVICTA
22 GF Score
Price ₹69.65
! 3 Warning Signs
View Full Analysis

What is Invicta Diagnostic EBIT?

Invicta Diagnostic NSE:INVICTA +3.88% 22 EBIT is ₹72.0 Mil as of Mar. 2026. GuruFocus rates NSE:INVICTA with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Invicta Diagnostic's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was ₹16.7 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹72.0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Invicta Diagnostic's annualized ROC % for the quarter that ended in Mar. 2026 was 3.46%. Invicta Diagnostic's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 18.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Invicta Diagnostic's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 10.44%.

Invicta Diagnostic  (NSE:INVICTA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Invicta Diagnostic's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=22.342 * ( 1 - 50.06% )/( (283.604 + 361.345)/ 2 )
=11.1575948/322.4745
=3.46 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=349.003 - 46.017 - ( 19.382 - max(0, 58.382 - 101.124+19.382))
=283.604

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=602.487 - 19.009 - ( 222.133 - max(0, 71.596 - 343.075+222.133))
=361.345

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Invicta Diagnostic's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=33.454/( ( (155.8 + max(20.248, 0)) + (191.895 + max(-31.349, 0)) )/ 2 )
=33.454/( ( 176.048 + 191.895 )/ 2 )
=33.454/183.9715
=18.18 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(26.904 + 5.618 + 46.108) - (46.017 + 0 + 12.365)
=20.248

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.725 + 5.938 + 4.284) - (19.009 + 0 + 28.287)
=-31.349

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Invicta Diagnostic's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=72.038/690.216
=10.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invicta Diagnostic EBIT Related Terms

Invicta Diagnostic EBIT Historical Data

* Premium members only.

The historical data trend for Invicta Diagnostic's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invicta Diagnostic EBIT Chart

Invicta Diagnostic Annual Data
Trend Mar24 Mar25 Mar26
EBIT
51.80 67.94 72.04

Invicta Diagnostic Semi-Annual Data
Mar24 Mar25 Sep25 Mar26
EBIT 0.00 0.00 55.31 16.73

NSE:INVICTA vs TMO, DHR, IDXX: EBIT Comparison

For the Diagnostics & Research subindustry, Invicta Diagnostic's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invicta Diagnostic EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Invicta Diagnostic's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Invicta Diagnostic's EV-to-EBIT falls into.


NSE:INVICTA
22GF Score
Invicta Diagnostic Ltd NSE:INVICTA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invicta Diagnostic EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹72.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹72.0 Mil mean?
Invicta Diagnostic (NSE:INVICTA) has a EBIT of ₹72.0 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Invicta Diagnostic.
Is Invicta Diagnostic's EBIT too high?
Invicta Diagnostic's current EBIT is ₹72.0 Mil. Overall, Invicta Diagnostic has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Invicta Diagnostic's EBIT compare to TMO and DHR?
Invicta Diagnostic's EBIT of ₹72.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Invicta Diagnostic. Invicta Diagnostic's current EBIT is ₹72.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invicta Diagnostic stock overvalued right now?
Invicta Diagnostic (NSE:INVICTA) has a current EBIT of ₹72.0 Mil. The current EBIT is ₹72.0 Mil. Invicta Diagnostic's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Invicta Diagnostic (NSE:INVICTA), the current EBIT is ₹72.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invicta Diagnostic Business Description

Address Western Express Highway, Office No. 1012, 10th Floor, Hubtown Viva CHS Ltd, Mogra Village, Near Shankarwadi, Jogeshwari East, Mumbai, MH, IND, 400 060
Invicta Diagnostic Ltd is engaged in the business of medical and diagnostic services and operates diagnostic centres providing medical testing and allied healthcare services in the Mumbai Metropolitan Region. The Company runs a diagnostic chain comprising seven diagnostic centres and one centralised laboratory across MMR in Maharashtra and operates under a hub and spoke model with a flagship hub in Thane, additional hub centres, spoke centres, and a centralised laboratory. Its service offerings include radiology and imaging, pathology and clinical laboratory tests, teleradiology, and services such as ultrasound, X Ray, CT scan, MRI scan, PET scan, and cardiac diagnostics, with patient convenience supported through home sample collection, house calls, and multiple report delivery options.
22GF Score

Get the complete analysis for NSE:INVICTA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹69.65
Price